- Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD
-
Suzuki H, Shimose S, Iwamoto H, Niizeki T, Kawaguchi T
- KMID: 2554431
- Clin Mol Hepatol.
- 2024 Apr;30(2):263-265.
- doi: 10.3350/cmh.2023.0557
-
- CITED
-
- Close
- SHARE
-
- Close
- Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma
-
Iwamoto H, Shimose S, Niizeki T, Koga H, Torimura T, The Kurume Liver Cancer Study Group of Japan
- KMID: 2531380
- Clin Mol Hepatol.
- 2022 Jul;28(3):575-579.
- doi: 10.3350/cmh.2022.0047
-
- CITED
-
- Close
- SHARE
-
- Close
- Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma
-
Shimose S, Koya S, Kawaguchi T, Hirota K, Yoshio S, Niizeki T, Matsuse H, Torimura T
- KMID: 2520844
- Clin Mol Hepatol.
- 2021 Oct;27(4):616-619.
- doi: 10.3350/cmh.2021.0258
-
- CITED
-
- Close
- SHARE
-
- Close
